6590-95-0

Basic information

• Product Name: 2,6-DICHLOROPHENYL ISOTHIOCYANATE
• Synonyms: 1,3-Dichloro-2-isothiocyanatobenzene;2,6-DICHLOROPHENYL ISOTHIOCYANATE;2,6-Dichlorophenyl isothiocyanate, 98+%;1, 3-Dichloro-2-isothiocyanto benzene;2,6-Dichlorophenyl isothiocyate, 98%
• CAS NO: 6590-95-0
• Molecular Formula: C₇H₃Cl₂NS
• Molecular Weight: 204.08
• EINECS: -0
• Product Categories: Organic Building Blocks;Sulfur Compounds;Thiocyanates/Isothiocyanates
• Mol File: 6590-95-0.mol
• Article Data: 12

Chemical Properties

• Melting Point: 38-42 °C(lit.)
• Boiling Point: 122-124°C 8mm
• Flash Point: >230 °F
• Appearance: /
• Density: 1.37 g/cm³
• Vapor Pressure: 0.00181mmHg at 25°C
• Refractive Index: 1.614
• Storage Temp.: 2-8°C
• Sensitive: Moisture Sensitive
• BRN: 639061
• CAS DataBase Reference: 2,6-DICHLOROPHENYL ISOTHIOCYANATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLOROPHENYL ISOTHIOCYANATE(6590-95-0)
• EPA Substance Registry System: 2,6-DICHLOROPHENYL ISOTHIOCYANATE(6590-95-0)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3261 8/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: II
• Hazardous Substances Data: 6590-95-0(Hazardous Substances Data)

Usage

Description

2,6-Dichlorophenyl isothiocyanate, an isothiocyanate derivative, is synthesized using 2,6-dichlorobenzaldehyde oxime as a starting reagent. It is a chemical compound with potential applications in various industries due to its unique properties.

Uses

Used in Pharmaceutical Industry:
2,6-Dichlorophenyl isothiocyanate is used as a precursor for the synthesis of 1-(2-aminoethyl)-2-cyano-3-(2,6-dichlorophenyl)guanidine. This synthesized compound has potential applications in the development of pharmaceuticals, particularly those targeting specific medical conditions.
In the synthesis process, 2,6-dichlorophenyl isothiocyanate serves as a crucial intermediate, contributing to the formation of the final product with desired therapeutic properties. Its role in the pharmaceutical industry highlights the importance of understanding and utilizing chemical compounds for the development of new drugs and treatments.

InChI:InChI=1/C7H3Cl2NS/c8-5-2-1-3-6(9)7(5)10-4-11/h1-3H

Upstream product

• 463-71-8 thiophosgene 
• 608-31-1 2,6-Dichloroaniline 
• 2904-62-3 2,6-dichlorobenzonitrile N-oxide 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 17356-08-0 thiourea 
• 28010-77-7 1-Benzoyl-1,3-dibenzylthioharnstoff 
• 37143-74-1 1-mesityl-3-phenylthiourea 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 33663-43-3 2,6-dichloroaniline hydrochloride 
• 591-08-2 acetylthiourea 
• 96938-54-4 N-benzoyl-N′-(2,4,6-trichlorophenyl)-thiourea 
• 3385-55-5 N,N'-dibenzhydryl-thiourea 
• 4921-83-9 1-benzoyl-3-(4-chloro-phenyl)-thiourea 

Downstream Products

• 64892-90-6 (3-cyclopropyl-5-methyl-3H-thiazol-2-ylidene)-(2,6-dichloro-phenyl)-amine 
• 65295-77-4 1-(2,6-dichlorophenyl)-3-[2-(1-piperidino)ethyl]-2-thiourea 
• 75257-64-6 1-(2,6-Dichloro-phenyl)-3-(2-hydroxy-ethyl)-thiourea 
• 115934-15-1 3-(2,6-Dichloro-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one 
• 75257-70-4 1-(3-Amino-propyl)-3-(2,6-dichloro-phenyl)-thiourea 
• 185116-66-9 3-(2,6-dichlorophenyl)imidazolidine-2-thione 
• 187866-55-3 2-[3-(2,6-dichlorophenyl)-thioureido]-acetamide 
• 367265-88-1 N-(2,6-dichlorophenyl)triisopropylphosphoniothiocarbonyl amide 
• 6590-91-6 1-(2,6-dichlorophenyl)thiourea 
• 709040-12-0 1-(8-amino-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,6-dichloro-phenyl)-thiourea 
• 333458-24-5 1-(8-amino-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-(2,6-dichlorophenyl)thiourea 
• 1027824-76-5 1-(8-amino-4,4-diethyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,6-dichloro-phenyl)-thiourea 
• 1027595-95-4 1-(8-amino-4-isobutyl-4-methyl-1,3-dioxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-3-(2,6-dichloro-phenyl)-thiourea 

Relevant articles and documents

Heterocyclic compounds as FGFR4 inhibitors

The present invention provides heterocyclic compounds as selective inhibitors of fibroblast growth factor receptor 4 (FGFR4), pharmaceutical compositions containing the compounds, methods of preparingthe compounds, and methods of treating cell proliferative diseases, such as cancer, using the compounds of the invention.

NOVEL FLAVONE BASED EGFR INHIBITORS AND PROCESS FOR PREPARATION THEREOF

The present invention discloses a novel EGFR inhibitor compound of formula (1), process for preparation thereof and methods of treating abnormal cell growth in mammals by administering the compounds of formula (1). wherein, R is selected from hydrogen, alkyl, nitro, halogens such as chlorine, bromine, fluorine and iodine; Rl= hydrogen, alkyl, alkoxy, aryl, nitro, halogens such as chlorine, bromine, fluorine and iodine, trifluoromethyl, thioalkyl, trifluromethoxy, trialkylsilyl.

Tricyclic Compounds As mPGES-1 Inhibitors

The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.